(LOS ANGELES) — Dr. Ali Khademhosseini, Ph.D., CEO and Director of the Terasaki Institute for Biomedical Innovation (TIBI), is honored with the 2024 Andreas Acrivos Award for Professional Progress in Chemical Engineering by the American Institute of Chemical Engineers (AIChE). This distinguished honor recognizes outstanding progress in the field of chemical engineering.
(LOS ANGELES) – Researchers at the Terasaki Institute for Biomedical Innovation have been awarded a multi-million grant from the National Institutes of Health (NIH) to advance research in organ transplantation and antibody-mediated rejection. This funding will facilitate the development of an innovative multi-organs-on-a-chip platform aimed at transforming our understanding of transplant rejection and immune tolerance.
Developing Breakthrough Contact Lens Technology for Mental Health Monitoring
(LOS ANGELES) – Yangzhi Zhu, Ph.D., Assistant Professor at the Terasaki Institute for Biomedical Innovation (TIBI), has been awarded the prestigious 2024 NARSAD Young Investigator Grant for his groundbreaking work on a lab-on-a-contact lens (LoCL) system. This innovative technology is designed to monitor mental health by providing real-time, non-invasive tracking of panels of key biomarkers, from the wearer’s tears.
(LOS ANGELES) – In a significant leap forward for healthcare equity and accessibility, researchers at the University of Victoria and the Terasaki Institute for Biomedical Innovation (TIBI) have developed a revolutionary system that combines remote health monitoring and drug delivery using 3D-printed hollow microneedles. This innovative approach, detailed in a recent study published in Advanced Healthcare Materials, promises to transform healthcare delivery, particularly for those in underserved or remote regions.
(LOS ANGELES) - An extensive analytical study performed at the Terasaki Institute and published in Frontiers in Immunology highlights the crucial role of tissue-resident memory T cells and how they influence the immune environment of patients with non-small cell lung cancer and their overall prognosis.
(LOS ANGELES) -The team created a photocrosslinkable bioink from egg whites through methacryloyl modification. This EWMA bioink offers several advantages that make it suitable for bioprinting applications. They provide abundant proteins, ensuring a nutrient-rich environment for cell growth. These bioinks exhibit excellent biocompatibility and bioactivity, crucial for successful tissue engineering.
(LOS ANGELES) – Dr. Ali Khademhosseini, CEO of the Terasaki Institute for Biomedical Innovation (TIBI), has been named the recipient of the prestigious 2024 Biomaterials Global Impact Award. This distinguished honor recognizes his outstanding research accomplishments and pioneering innovations in biomaterials science and engineering.
(LOS ANGELES) - Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have unveiled a pioneering study shedding light on the intricate mechanisms underlying Alzheimer's disease (AD). The study, titled "Effects of amyloid-β-mimicking peptide hydrogel matrix on neuronal progenitor cell phenotype," represents a significant leap forward in understanding the interplay between amyloid-like structures and neuronal cells.